Asiye Nur Meltem KABLAN, MEHMET ERMAN OR, Abdülkadir UYSAL

Veteriner pratiğinde geniş antifungal spektrumlu yeni triazol: Vorikonazol

Azoller artan öneme sahip invaziv fungal infeksiyonların tedavisinde özellikle immunolojik açıdan sorunlu olan hastalarda anahtar rol üstlenirler. Vorikonazol Aspergillus, Candida, Cryptococcus neoformans ve daha az görülen bazı küfler gibi klinik olarak önemli olan fungal patojenlere karşı geniş spektrumlu güçlü aktivitesiyle ikinci jenerasyon yeni triazol antifungal ajandır. Son zamanlarda yapılan pek çok çalışma vorikonazolün klinik etkinliğinin oldukça büyük olduğunu göstermiştir. Derlememizde vorikonazolün veteriner pratiğinde kullanımı hakkında bilgi verilmektedir.

Clinical use of voriconazole, a new wide-spectrum triazole, in veterinary practice

Azoles have maintained a key role in the treatment of invasive fungal infections which have a growing importance, especially in immunocompromised patients. Voriconazole is a second generation new triazole antifungal agent with potent activity against many clinically significant fungal pathogens, including Aspergillus, Candida, Cryptococcus neoformans and some less common moulds. Several recent studies have indicated that voriconazole is also highly effective in therapy of clinical cases. In our review it is aimed to give further information about voriconazoles’ clinical effects and use in veterinary practice.

PDF

___

1. Andes D, Marchillo K, Stamstad T, Conklin R: In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model, Antimicrob Agents Chemother 2003;47(10):3165-9.
2. Anonim: Voriconazole: new preparation, invasive aspergillosis: benefits to be confirmed, Prescrire Int 2004;13(69):13-6.
3. Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents: pharmacokinetics, safety and efficacy, Drugs 2004;64(18):1997-2020.
4. Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ: Topical and oral voriconazole in the treatment of fungal keratitis, Am J Ophtalmol 2007;143(1):151-3.
5. Clode AB, Davis JL, Salmon J, Michau TM, Gilger BC: Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses, Am J Vet Res 2006;67(2):296-301.
6. Colitz CM, Latimer FG, Cheng H, Chan KK, Reed SM, Pennick GJ: Pharmacokinetics of voricona- zole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses, Am J Vet Res 2007;68(10):1115-21.
7. Davis JL, Salmon JH, Papich MG: Pharmacokinetics of voriconazole after oral and intravenous administration to horses, Am J Vet Res 2006;67(6):1070-5.
8. De Pauw BE: New antifungal agents and prepara tions, Int J Antimicrob Agents 2000;16(2):147-50.
9. Elad S, Bitan M, Olshtain-Pops K et al: Successful treatment of oral invasive aspergillosis with voriconazole; Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99(4):428.
10. Herbrecht R: Voriconazole: therapeutic review of a new azole antifungal, Expert Rev Anti Infect Ther 2004;2(4):485-97.
11. Hoffman HL, Rathbun RC: Review of the safety and efficacy of voriconazole, Expert Opin Investig Drugs 2002;11(3):409-29.
12. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HE: Voriconazole, Clin Ther 2003; 25(5):1321-81.
13. Keady S, Thacker M: Voriconazole in the treatment of invasive fungal infections, Intensive Crit Care Nurs 2005;21(6):370-3.
14. Kirkpatrick WR, Perea P, Coco BJ, Patterson TF: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis, Antimicrob Agents Chemother 2002;46(8):2564-8.
15. Kofla G, Ruhnke M: Voriconazole: Review of a broad spectrum triazole antifungal agents, Expert Opin Pharmacother 2005;6(7):1215-29.
16. Muijsers RB, Goa KL, Scott LJ: Voriconazole in the treatment of invasive aspergillosis, Drugs 2002;62(18):2655-66.
17. Polak A: Antifungal therapy-state of the art at the begining of the 21st century, Prog Drug Res 2003;Spec No:59-190.
18. Rochette F, Engelen M, Vanden Bossche H: Antifungal agents of use in animal health-practical applications, J Vet Pharmacol Therap 2003;26(1):31-53.
19. Roffey SJ, Cole S, Comby P et al: The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog and human, Drug Metab Dispos 2003;31(6):731-41.
20. Rubin AI, Bagheri B, Scher RK: Six novel antimycotics, Am J Clin Dermatol 2002;3(2):71-81.
21. Shirasawa S, Nagino K: Voriconazole-medicalneeds, evidence, potentional for the future, Nippon Isinkin Gakkai Zasshi 2005;46(4):223-8.
22. The Merck Veterinary Manual (Ed.:Kahn CM): 9th Edition, Merck and Co. Inc., Whitehouse Station NJ (2005).
23. Theuretzbacher U, Ihle F, Derendorf H: Pharmacokinetic/pharmacodynamic profile of voriconazole, Clin Pharmacokinet 2006;45(7):649-63.
24. Tortorano AM, Prigitano A, Dho G, Piccinini, R, Dapra V, Viviani MA: In vitro activity of conventional antifungal drugs and natural essences againts the yeast-like alga Prototheca, J Antimicrob Chemother 2008;61(6):1312-4.
25. Tsuchimori N, Hayashi R, Kitamoto N et al: In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with broad antifungal spectrum, Antimicrob Agents Chemother 2002;46(5): 1388-93.
26. Wolff M, Bouadma L, Mourvillier B: Emerging azole antifungals, Therapie 2006;61(3):227-33.